Navigation Links
VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
Date:8/1/2008

SAN FRANCISCO, Aug. 1 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Rebecca A. Taub, MD, VIA's senior vice president of research and development, will present at the 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress taking place August 4-7 in Boston, MA.

The presentation details are as follows:

Date/Time: Wednesday, August 6, 2008: 2:20-2:50 p.m. ET

Location: World Trade Center Boston & Seaport Hotel

Session: Translational Medicine IV: Case Studies of Translational

Approaches from Preclinical to Clinical Proof-of-Concept

Title: Innovative Clinical Trial and Biomarker Approaches To Demonstrate

the Role Of Leukotrienes and 5LO Inhibition in Atherosclerotic Disease

"VIA has taken an innovative approach in its design of Phase 2 clinical trials for VIA-2291, its lead compound," said Dr. Taub. "I am excited to share with conference participants our view on the value of innovative techniques in the design of critical clinical trials, particularly with regards to serum inflammatory biomarkers, analyses of atherosclerotic plaque tissue, and non-invasive imaging."

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
2. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
3. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
5. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
6. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
7. Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
8. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
9. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
10. Poniard Pharmaceuticals Announces Upcoming Conference Participation
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 The global ... a research report by Transparency Market Research (TMR). The ... Inc., and AbbVie Inc., accounted for a share of ... players in this market are focusing aggressively on mergers, ... which is likely to lead to market consolidation in ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
(Date:3/22/2017)... Pa. , March 22, 2017 /PRNewswire/ ... global independent provider of product and service ... today that it has acquired EPL Archives, ... supports customers across the entire regulated product ... archive sample, document storage and ancillary services. ...
(Date:3/22/2017)... ... , ... Okyanos Cell Therapy has announced Tallahassee, FL will be the next ... Cell Therapy: The Next Phase in the Evolution of Medicine.” As the Bahamas’ first ... Therapy Act, Okyanos maintains a mission to help “no-option” patients and those with ...
Breaking Biology Technology:
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics ... ...
(Date:3/13/2017)... 13, 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other ... identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching on the ...
Breaking Biology News(10 mins):